

## Prof. Luigi Tavazzi

### Curriculum Vitae (breve)

Indirizzo lavorativo: GVM Hospitals of Care and Research  
Villa Maria Cecilia Hospital  
Via Corriera, 1  
48010 Cotignola (RA)  
Italy

Telefono: +39 0545 217564

TeleFax: +39 0545 217327

Email: [direzionescientifica@gvm-vmc.it](mailto:direzionescientifica@gvm-vmc.it)

### RUOLO PRESENTE

Direttore Scientifico del Gruppo Villa Maria, con sede operative presso l'ospedale Villa Maria Cecilia, Via Corriera, 1 Cotignola (RA).

### RUOLI IN COMITATI E SOCIETA' NAZIONALI ED INTERNAZIONALI

- *Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)*  
Vice-presidente (1992-94), Presidente (1994-96)
- *Council on Cardiac Rehabilitation of the World Federation of Cardiology*  
Vice-presidente e Presidente eletto (1994-1995).
- *Federazione Italiana di Cardiologia (FIC)*  
Vice-presidente (1998-2001), Presidente (2001- 2004)
- *Ministero della Salute*  
Membro del Comitato per la Prevenzione del Rischio Cardiovascolare (2005-presente)
- *ESC (European Society of Cardiology- Società Europea di Cardiologia):*
  - Segretario ('85-'86), ViceChairman ('87-'88), Chairman ('89-'90) del *Working Group on Cardiac Rehabilitation*.
  - Membro del *Credential Committee* (1996-98), *Executive Scientific Committee* (1996-2000), *Nominating Committee* (1998-2000), *European Heart Survey Committee* (2004-2006), *Cardiovascular Round Table* (2004-presente), *Study Group on Surveys and on Acute Heart Failure* della *Association on Heart Failure* (2005-presente).
  - Segretario (2004-2005), Vice-chairman (2006-2008) e Chairman (2008-10) del *Working Group on Myocardial and Pericardial Diseases*
  - Chairman del *Regulatory Subcommittee* del Committee on European Affairs della ESC (2008-2010)
  - Membro del Comitato per l'Organizzazione del Congresso della Società Europea di Cardiologia dei Congressi 2008-2010.

### RUOLI IN TRAIL CLINICI INTERNAZIONALI IN CORSO

- TRIALS
  - GISSI-HF (Chairman del Comitato Esecutivo)
  - HORIZON (Chairman del DSMB)
  - SENSE-HF (Membro dello Steering Committee)
  - I-PRESERVE (Responsabile nazionale)
  - EMPHASIS (Membro del DSMB)
  - CANDHEART (Chairman del DSMB)

- SHIFT (Membro del Comitato Esecutivo)
- REVERSE trial (Responsabile del Core Lab ecocardiografico)
- PROSPECT trial (Membro dello Steering Committee)
- OPTILINK (Membro del DSMB)

- REGISTRIES

- IN-HF (Chairman dello Steering Committee)

- SURVEYS

- URGENT (Membro dello Steering Committee)

AREE DI INTERESSE SCIENTIFICO:

- Approccio diagnostico, valutativo e terapeutico della cardiopatia ischemica
- Aspetti fisiopatologici e clinici dello scompenso cardiaco
- Patofisiologia e clinica del sistema nervoso autonomo

## PUBBLICAZIONI SCIENTIFICHE NEGLI ULTIMI 5 ANNI

### **2004**

Ghio S et al. Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration. *Eur Heart J* 2004; 25: 571-8.

Temporelli et al. Doppler-derived deceleration time as strong prognostic marker of left ventricular remodeling and survival after acute myocardial infarction. Results of the GISSI-3 Echo Substudy. *J Am Coll Cardiol* 2004; 43: 1646-53.

Mann DL et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomised etanercept worldwide evaluation (RENEWAL). *Circulation* 2004; 109: 1594-1602.

Dirksen MT et al on behalf of the PARI-MI Investigators. The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty. Safety and efficacy of a novel tetrapeptide, ITF-1697. *Eur Heart J* 2004; 25: 392-401.

Tavazzi L. Which strategy should be used for postinfarct treatment? *Dialogues Cardiovasc Med.* 2004; 9: 101-7.

Tavazzi L et al. Participation vs education: the GISSI story and beyond. *Am Heart J* 2004; 148: 222-9.

Tavazzi L et al on behalf of the GISSI-HF investigators. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. *Eur J Heart Fail* 2004; 6: 635-41.

Mannucci PM et al. Manifesto per la rinascita della sanità. *Ricerca&Pratica* 2004-II pensiero Scientifico Editore

Pasotti M et al Genetic predisposition to heart failure. *Med Clin N Am* 2004; 1173-92.

Brambilla N et al. Directional coronary atherectomy plus stent implantation vs left internal mammary artery bypass grafting for isolated proximal stenosis of the left anterior descending coronary artery. *Cathet and Cardiovasc Interventions* 2005; 2005; 64: 45-52

Tavazzi L et al. A research project focusing on uncommon aspects and novel markers in congestive heart failure. Critical evaluation of multicentre research management. *Eur Heart J* 2004; 6 Suppl F: F1-F6

Ghio S et al. Plasma brain natriuretic peptide is a marker of right ventricular overload in pulmonary hypertension associated to HIV infection. *Eur Heart J* 2004; 6 Suppl F: F35-F 39

Arbustini E et al Cardiomyology: an attempt to link structural cardiac and skeletal muscle damage in patients with dilated cardiomyopathy. *Eur Heart J* 2004; 6 Suppl F: F40-F53

Repetto A et al. Rescreening of "healthy" relatives of patients with dilated cardiomyopathy identifies subgroups at risk of developing the disease. *Eur Heart J* 2004; 6 Suppl F: F54-F60

Campana C et al. The evaluation of right ventricular performance in different clinical models of heart failure. *Eur Heart J* 2004; 6 Suppl F: F61-F567

Mojoli F et al. Respiratory fatigue in patients with acute cardiogenic pulmonary edema. *Eur Heart J* 2004; 6 Suppl F: F74-F80

Mortara A et al. A multi-country randomized trial of the role of a new telemonitoring system in CHF: the HHH study. Rationale, study design and protocol. *Eur Heart J* 2004; 6 Suppl F: F99-F102

Scelsi L et al. Una possibile alternativa alla terapia infusiva con i farmaci isotropi positivi tradizionali. *Recenti progressi in medicina* 2004; 95 : 37683.

Breithardt G et al. Cardiac resynchronization and defibrillation therapies – International clinical and scientific update. *Hjerteforum* 2004; 4: 50-52.

Scelsi L et al. Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions. *Ital Heart J* 2004; 5: 618-23

Scelsi L et al. Levosimendan in heart failure. *Recent Progr. Med* 2004; 95: 376-83

Zile M et al. MCC-135 G01 Investigators. A phase II, double blind, randomised, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design.. *J Card Fail* 2004; 10: 193-9

Popescu BA et al. GISSI-3 Echo Substudy Investigators. Left atrium remodeling after acute myocardial infarction (results of the GISSI-3 Echo Substudy). *Am J Cardiol.* 2004 May 1; 93: 1156-9.

Canosi U et al. Angiotensin-converting enzyme insertion/deletion polymorphism and risk of restenosis after directional coronary atherectomy followed by stent implantation. *Thromb Haemost.* 2004 Apr; 91:795-800.

Tavazzi L et al. The evolving rationale of heart failure therapy *Dialogues* 2004; 9: 207-222

## **2005**

Brambilla N et al. et al. Directional coronary atherectomy plus stent implantation vs left internal mammary artery bypass grafting for isolated proximal stenosis of the left anterior descending coronary artery. *Cathet and Cardiovasc Interventions* 2005; 2005; 64: 45-52.

Tavazzi L. The ranolazine clinical experience. *Eur Heart J Suppl I* 2004; 6: 11-12

Maggioni AP et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. *J of Cardiac Fail* 2005; 11: 91-98.

Popescu BA et al. Right ventricular functional recovery after acute myocardial infarction: relation with left ventricular function and interventricular septum motion. *GISSI-3 echo study.* *Heart* 2005; 91: 484-88.

Massa M et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. *Blood* 2005; 105: 199-206.

Cheuk-Man Y et al. Predictors of response to cardiac resynchronization therapy (PROSPECT) – study design. *Am Heart H* 2005; 149: 600-6.

Daly C et al. The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina. *Eur Heart J* 2005; 26: 996- 1010

Daly C et al. The initial management of stable angina in Europe, from the Euro heart Survey. *Eur Heart J* 2005; 26: 1011-1022.

Repetto A et al. Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander? *Eur Heart J* 2005; 26: 1519-27

Yu CM et al. Predictors of response to cardiac resynchronization therapy (PROSPECT) – study design. *Am Heart J* 2005; 149: 600-605.

Swedberg K et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology *Eur Heart J* 2005; 26: 1115-40

Majani G et al. Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the valsartan heart failure trial. *J Card Fail* 2005; 11: 253-9

Komajda M et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. *Eur Heart J* 2005; (pub ahead of print)

Lettingo M et al. Therapeutic approach in patients with stable angina. *Ital Heart J* 2005; 6: 1-8.

Cleland JG et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med* 2005; 14: 1539-49.

Cleland JG et al. Baseline characteristics of patients recruited into the CAREHF study. *Eur J Heart Fail* 2005; 7: 205-14.

Flather MD et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005; 26: 215-25

Tavazzi L. Ranolazine, a new antianginal drug – Future in Cardiology 2005 ;1:447-56

GISSI- Group. Right-ventricular function after acute myocardial infarction . *Nature Clinical Practice Cardio Medicine* 2005, 2: 230.

Cleland JGF et al, for the CARE-HF Study Investigators. Cardiac Resynchronization therapy in heart failure *N Engl J Med* 2005; 353: 2 205-6

Levantesi G et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. *J Am Coll cardiol* 2005; 46: 277-83.

Macchia A et al. Left ventricular systolic dysfunction , total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. *Eur J of Heart Fail* 2005; 7: 904-9.

Tavazzi L et al. Leitliniengerechte herzinsuffizienzbehandlung in Deutschland. Ergebnisse der MAHLER – Studie. *Deutsche Medizinische Wochenschrift* 2005; 130: 2191-97.

Abustini E et al. Identification of sixty-two novel and twelve known FBN1 mutations in 81 unrelated probands with Marfan syndrome and other fibrillinopathies. *Hum Mutat* 2005; 26: 494.

Arbustini E et al. Gene symbol: LMNA disease cardiomyopathy, dilated, with conduction tissue defect 1 Hum Genet 2005; 117: 300

Opasich C et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anemia in patients with chronic heart failure. Eur Heart J 2005; 26: 2232-7

Tavazzi L. Clinical assessment of patients with stable angina. Medicographia 2005; 82: 15-20

Swedberg K, for the writing Committee of the ESC Guidelines on the Diagnosis and Treatment of CHF. Letter to the Editor. Eur Heart J 2005; 26: 2473.

Tavazzi et al. La ricerca clinica sul farmaco in Italia. Bollettino Società Italiana Medicina Interna 2005 Anno VIII n. 3 Pag. 11-15

Tavazzi L et al. Observational research: a fundamental tool for clinical practice. Ital Heart J Suppl 2005; 6: 82-9.

Ghio S et al. Right ventricular dysfunction in advanced heart failure. Ital Heart J 2005; 6: 852-5.

Flesch M et al. Adherence to guidelines in CHF therapy in Germany. Dtsch Med Wochenschr. 2005 Sep 30;130(39):2191-7.

Daly C et al. Gender differences in the management and clinical outcome of stable angina. Circulation 2006; 113: 490-8

Fattore G et al. Per il Gruppo di Studio congiunto Federazione Italiana di Cardiologia-Assobiomedica "Valutazione del Modello CRT-Eucomed". L'impatto economico della terapia di resincronizzazione in pazienti con scompenso cardiaco. Evidenze disponibili e valutazione del modello CRT-Eucomed per l'analisi del rapporto costo-efficacia. Ital Heart J Suppl 2005; 6 (12): 796-803).

Tavazzi L et al. La ricerca osservazionale. Uno strumento fondamentale per la pratica clinica. Ital Heart J Suppl 2005; 6:682-9

Gheroghiade M et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005; 112: 3958-68.

Arbustini E et al. Desmin accumulation restrictive cardiomyopathy and atrioventricular blocks associated with desmin gene defects. Eur J Heart Fail: 2005; Dec 21 (epub ahead of print).

Ghio S et al. Baseline echocardiographic characteristics of heart failure patients enrolled in a large European multicentre trial (Cardiac Resynchronization Heart Failure study). Eur J Echocardiogr 2005; Dec 2 (epub ahead of print).

Macchia A et al. Determinants of late-onset heart failure in myocardial infarction survivors: GISSI Prevenzione trial results. Rev Esp Cardiol 2005; 58: 1266-72.

Giannuzzi P et al. Global Secondary Prevention strategies to Limit event recurrence after myocardial infarction: the GOSPEL study. A trial from the Italian Cardiac Rehabilitation Network: rationale and design. Eur J Cardiovasc Prev Rehabil 2005; 12: 555-561.

Arbustini E et al. Gene symbol: LMNA . Disease: EDMD2. Hum Genet 2005; 117: 294.

Task Force sulla Diagnosi e Trattamento dello Scompenso Cardiaco Cronico della Società Europea di Cardiologia. Linee guida per la diagnosi e il trattamento dello scompenso cardiaco cronico: riassunto esecutivo (revisione 2005) . Ital Heart J Suppl 2005; 6: 735-64

L. Tavazzi. La Cardiologia in Italia: situazione attuale e prospettive per il futuro. Il cardiologo italiano. Vademecum. Edizioni Hippocrates 2005, Milano- Volume 2 pagg 5-13

Tavazzi L. A new cardiovascular risk factor: obesity. The social and medical problem of overweight children and adolescents . Intern Journal of metabolism by Fax 2005; 37: 75

Magrini G et al. Rationale characteristics and study design of PREAMI. Ital Heart J 2005; Suppl 7: 14S-23S

Mortara A et al. Rehabilitation and models of domiciliary care of patients with chronic heart failure: preliminary results of the HHH study. Monaldi Arch Chest Dis. 2005; 64: 143-5

## **2006**

Macchia A, et al. A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardio (GISSI)-Prevenzione scoring. Am Heart J. 2006; 151:754.e7-754.e17.

Daly C et al. Gender differences in the management and clinical outcome of stable angina. Circulation 2006; 113: 490-8.

Ghio S et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006;27:562-8

Tavazzi L, From Guidelines to Registries. Acute Coronary syndromes a Handbook for clinical practice. 2006. Blackwell Publishing. Edited by E. Bertrand, B. King III.

Task Force sulla Diagnosi e Trattamento dello Scopenso Cardiaco Cronico della Società Europea di Cardiologia. Linee guida per la diagnosi e il trattamento dello scopenso cardiaco cronico: riassunto esecutivo (revisione 2005) . Ital Heart J Suppl 2005; 6: 735-64

Tavazzi L. The need to identify new targets for therapeutic intervention in angina . Eur Heart J Suppl 2006; 8: Suppl A - A3-A5.

The late sodium current: emerging involvement in cardiovascular disease and role as a target for potential new therapies in angina. Eur Heart J Suppl 2006; 8: Suppl A - A1-A25. Edited by PA Poole- Wilson and L Tavazzi

Linde C, Gold M, Abraham WT, et al. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure . the Resynchronization reVERSE Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Am Heart J 2006; 151: 288-94.

The PREAMI Investigators Effects of angiotensin –converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome. Arch Intern Med 2006; 166; 659-666

Tavazzi L. A proposito di defibrillatori impiantabili e linee guida. G Ital Cardiol 2006; 228: 233

Tavazzi L et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J 2006 27: 1207-1215

Marchioli R et al. On behalf of the GISSI-Prevenzione Investigators. Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI-Prevenzione trial. *J Cardiovasc Med* 2006; 7: 347-350.

Daly C et al. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina : findings from the euro heart survey of stable angina. *Eur Heart J* 2006; 27: 1298-304.

Tavazzi L et al. Note sulla ricerca clinica sul farmaco in Italia. *G. Ital Cardiol* 2006; 7: 62-67.

Tavazzi L et al. Can If inhibition help in congestive heart failure? *Dialogues in Cardiovasc Med* 2006; 11: 30-35

Opasich et al. Programme to improve the use of beta-blockers for heart failure in the elderly and in those with severe symptoms: Results of the BRING-UP 2 Study. *Eur J Heart Fail* 2006; 8: 649-57

Cleland JG et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure. *Eur Heart J* 2006; 27: 1928-32.

Pepine CJ et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease. *J Am Coll Cardiol* 2006; 47: 547-51.

Luigi Tavazzi et al on behalf of the Italian survey on Acute Heart Failure Investigators  
Nationwide survey on acute heart failure in cardiology ward services in Italy  
*Eur. Heart J*, May 2006; 27: 1207 - 1215.

Monte S et al. Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. *Eur Heart J* 2006 27:2217-23.

Cleland JGF et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure – the Cardiac Resynchronization Heart Failure(CARE-HF) trial extension phase. *Eur Heart J* 2006; publish ahead of print

Arbustini E et al. Desmin accumulation restrictive cardiomyopathy and atrioventricular block associated with desmin gene defects. *Eur J of Heart Fail* 2006; 8: 477-83

Lettera A. Fracassi, Risposta L. Tavazzi G *Ital Cardiol* 2006; 7: 508-509

Nieminen M et al. Euroheart Failure Survey II: a survey on hospitalized acute heart failure patients, description of population. *Eur Heart J* 2006; 27: 2725-36

Ghio S et al Baseline echocardiographic characteristics of the heart failure patients enrolled in a large European multicentre trial (Cardiac Resynchronisation Heart Failure study). *Eur J Echocardiography* 2006; 7: 373-8

Avanzini F et al High pulse pressure and low mean arterial pressure: two predictors of death after a myocardial infarction. *J Hypertens* 2006 24: 2377-2385.

Nieminen M et al. Euroheart Failure Survey II (EHFS): a survey on hospitalized acute heart failure patients, description of population. *Eur Heart J* 2006; 27: 2725-36.

Marchioli R et al. Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI-Prevenzione trial. *J Cardiovasc Med* 2006; 7: 347-50.

Daly CA et al. Predicting prognosis in stable angina – results from the Euro heart survey of stable angina: prospective observational study. *BMJ* 2006; 332: 262-7

L. Tavazzi Management e qualità. Una novità: appuntamenti periodici con l'IN-CHF . Ristrutturato e con acronimo cambiato in IN-HF (Italian Network on Heart Failure). G Ital Cardiol 2006; 7: 687-88.

Tavazzi L. Una novità: appuntamenti periodici con l'IN-CHF. G Ital Cardiol 2006; 7: 687-9

## 2007

Fruhwald FM et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 2007; 28: 1592-7.

Gras D et al on behalf of The CARE-HF Study Steering Committee and Investigators. Implantation of cardiac resynchronization therapy system in the CARE-HF trial: procedural success rate and safety. Europace 2007; 9:516-22.

Casella G et al. La frequenza cardiaca come obiettivo terapeutico dell'angina stabile. Ruolo delle terapie attuali e loro sottoutilizzo in Italia. G Ital Cardiol 2007; 8: 207-14.

Tavazzi L. Nebivolol for heart failure in the elderly. Expert Rev. Cardiovasc. Ther 2007; 5: 423-33

Richardson M et al on behalf of the CARE-HF Study Steering Committee and Investigators Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial. Eur Heart J 2007; 28: 1827-34.

De Luca L et al. Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy. Heart Fail Rev 2007; 12: 97-104.

Macchia A et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007; 153: 1037-47

Marchioli R et al. Efficacy of n-3 polyunsaturated fatty acids according to clinical characteristics of patients with recent myocardial infarction: insights from the GISSI-Prevenzione trial. J Cardiovasc 2007;8 suppl 1:S34-7

Ferrario M et al Early haemoglobin- independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur Heart J 2007; 28: 1805-1813.

Mozaffarian D et al. Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors. Lancet 2007; 370: 667-75.

Ghio S et al. Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. Eur J Heart Failure 2007; 9: 808-13.

Fox K et al. Resting heart rate in cardiovascular disease. J Am coll Cardiol 2007; 50: 823-30.

Brambilla N et al. Use of sirolimus-eluting stents for treatment of in-stent restenosis: long term –follow-up. J Cardiovasc Med 2007; 8: 699-705.

De Luca L et al. Acute Heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy . Heart Fail Rev 2007; 12: 97-104

Libetta C et al Intermittent haemodiafiltration in refractory congestive heart: BNP and balance of inflammatory cytokines. Nephrol Dial Transplant 2007; 22: 2013-19

Marchioli R et al. Efficacy of n-3 polyunsaturated fatty acids according to clinical characteristics of patients with recent myocardial infarction: insights from the GISSI-Prevenzione trial. *J Cardiovasc Medicine* 2007; 8: S3-S7.

Silletta MG et al. Coffee consumption and risk of cardiovascular events after acute myocardial infarction. Results from the GISSI-Prevenzione trial. *Circulation* 2007, 116: 2944-51.

Libetta C et al. Removal of BNP and inflammatory cytokines by haemodiafiltration in refractory heart failure-Reply – *Nephrol Dial Transpl* 2007; 22: 2094-5.

Marsan NA et al. Real-Time Three-Dimensional Echocardiography Permits Quantification of Left Ventricular Mechanical Dyssynchrony and Predicts Acute Response to Cardiac Resynchronization Therapy. *J Cardiovasc Electrophysiol*. 2007 Dec 20; [Epub ahead of print]

## 2008

Elliott P et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. *Eur Heart J*. 2008;29:270-76

Ajmone Marsan N et al. Left ventricular dyssynchrony assessed by two three-dimensional imaging modalities: phase analysis of gated myocardial perfusion SPECT and tri-plane tissue Doppler imaging. *Eur J Med Mol Imaging* 2008; 35: 166-73

Nieminen MS et al. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. *Eur J Heart Fail* 2008; 10: 140-48.

Caseau S et al. Responders to cardiac resynchronization therapy with narrow or intermediate QRS identified by simple echocardiographic indices of dyssynchrony: the DESIRE study. *European J Heart Fail* 2008;10: 273-80.

Chung ES et al. Results of the Predictors of Response to CRT (PROSPECT) trial. *Circulation* 2008;117:2608-2616.

Tavazzi L, Ambrosio G. Introduzione. Il rischio aterotrombotico "residuo" esiste? *G. Ital Cardiol* 2008;9 (Suppl 1-4):3S-5S

De Ferrari et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. *Eur J Heart Failure* 2008;10(6):550-555.

Macchia A, et al. Depression worsens outcomes in elderly patients with heart failure: an analysis of 18,117 patients in a community setting. *Eur J Heart Fail* 2008, 10: 714-721.

Cleland JGF et al. Predicting the Long-Term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response. A report from the CARE-HF trial. *J Am Coll Cardiol* 2008;52: 438-445.

GISSI-HF investigators (Tavazzi L, Chairman of the Steering Committee and Writing Committee). Effects of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo controlled trial. *The Lancet*, [www.thelancet.com](http://www.thelancet.com), published on line August 31, 2008 DOI:10.1016/S0140(08)61239-8.

GISSI-HF investigators (Tavazzi L, Chairman of the Steering Committee and Writing Committee). Effects of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo controlled trial. *The Lancet*, [www.thelancet.com](http://www.thelancet.com), published on line August 31, 2008 DOI:10.1016/S0140(08)61240-4.

